Lian­Bio re­jects Con­cen­tra bid; Tread­well cuts work­ers; As­traZeneca inks CAR-T deal

Plus news about Ipsen’s elafi­bra­nor, Har­mo­ny’s Phase II da­ta, an ac­tivist in­vestor’s let­ter to 2sev­en­ty bio, and Sanofi’s CD38 drug.

Tang’s Con­cen­tra strikes out with Lian­Bio: The US-Chi­nese com­pa­ny’s board unan­i­mous­ly re­ject­ed Con­cen­tra’s un­so­licit­ed ac­qui­si­tion bid for $4.30 per share plus a con­tin­gent val­ue right mech­a­nism. In May, Atea Phar­ma­ceu­ti­cals al­so de­clined a propo­si­tion from Tang’s shell com­pa­ny. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER